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Abstract 
Periodontitis is one of the most common chronic inflammatory diseases. The etiology is clearly bacterial and a number of putative 
bacterial pathogens have been associated with the disease, including Aggregatibacter actinomycetemcomitans, Tannerella forsythus 
and Porphyromonas gingivalis. Comparatively, little attention has been paid to the identification of health-associated and potentially 
beneficial bacterial species that may reside in the gingival sulcus. Probiotic technology represents a breakthrough approach to 
maintaining oral health by using natural beneficial bacteria, commonly found in healthy mouths, to provide a natural defense against 
those bacteria which are thought to be harmful to teeth and gums. This article endeavors to introduce the concepts of probiotics in 
periodontics. 
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Introduction 
Periodontitis is a multifactorial disease that 
encompasses the hard and soft tissue, microbial 
colonization (with or without invasion), inflammatory 
responses and adaptive immune responses. The 
complexity of the local tissue components, including 
bacteria and/or their products and virtually all aspects of 
host response mechanisms, has complicated our ability to 
elucidate the critical protective functions in the tissues and 
has continually provided evidence for the potential of host 
destructive factors as the ultimate causative parameters 
in the disease. [1] Conventional treatment modalities of 
periodontal disease include non-surgical and surgical 
management, which emphasizes mainly on mechanical 
debridement, often accompanied by antibiotics. These 
treatment modalities are aimed at eliminating the entire 
microflora irrespective of their pathogenicity. Due to the 
emergence of antibiotic resistance and frequent 
recolonization of treated sites with pathogenic bacteria, 
there was need for a new treatment paradigm to be 
introduced to periodontal disease. The need was fulfilled 
by introduction of Probiotics and bacterial replacement 
therapy in the field of periodontics. 
Probiotics and prebiotics 
Probiotics are defined as living microorganisms, 
principally bacteria, that are safe for human consumption 
and, when ingested in sufficient quantities, have beneficial 
effects on human health, beyond basic nutrition. This 
definition has been approved by the United Nations Food 
and Agriculture Organization (FAO) and the World Health 
Organization (WHO). [2] 
Prebiotics (i.e. inulin-type fructans, maltodextrin, 
fructooligosaccharides and galactooligosaccharides) have 
been defined as non-digestible oligosaccharides that 
affect the proliferation of resident commensal bacteria that 
may then exert probiotic effects. [3] More recently, the 
definition has been refined to include selectively 
fermented ingredients that allow specific changes in the 
composition and/or activity of the resident microflora that 
confer benefits upon host well-being and health. [4] 
Prebiotics and probiotics often work in synergy 
and, when combined in the same product, are known as 
synbiotics. It appears that synbiotics increase survival of 
probiotic bacteria, stimulating their growth in the intestinal 
tract and improving the balance of health-promoting 
bacteria. [5] 
 
History 
The dietary use of living microorganisms has a 
long history. Mention of cultured dairy products is found in 
the bible and the sacred books of Hinduism. Sacred milks 
and cultured dairy products such as kefir, koumiss, liben Journal of Medicine and Life Vol. 4, Issue 4, October‐December 2011 
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and dahi, were often used therapeutically before the 
existence of microorganisms was recognized. [6] 
Probiotics have been used for decades in 
fermented products, but potential use of probiotics as a 
nutritional medical therapy has not been formally 
acknowledged. [7] Metchnikoff was the first to state that 
probiotics could provide a health benefit, and proposed 
that Bulgarian people had a longer longevity due to 
fermented milk containing viable bacteria. “Probiotic” 
term, as opposed to “antibiotic”, was initially proposed by 
Lilley and Stillwell in 1965. First probiotic species to be in-
troduced in research was Lactobacillus acidophilus by 
Hull et al. in 1984; followed by Bifidobacterium bifidum by 
Holcombh et al. in 1991. 
In  1994, the World Health Organization 
deemed probiotics to be the next-most important immune 
defense system  when commonly prescribed antibiotics 
are rendered useless by antibiotic resistance. These 
incidences paved way for a new concept of probiotics in 
medicine and dentistry. [8-10] 
 
Mechanisms of action 
Probiotics 
The mechanism of action vary according to the 
specific strain or combinations of strains used, the 
presence of prebiotics and the condition that is being 
treated, as well as the stage of the disease process in 
which the probiotic is administered. [11] There are 
common themes emerging in studies of the modes of 
action of probiotics and numerous mechanisms have 
been proposed [11,12] including: 
  Inhibition of pathogen adhesion, colonization and 
biofilm formation  
  Induction of expression of cytoprotective proteins 
on host cell surfaces 
  Inhibition of collagenases and reduction of 
inflammation associated molecules 
  Stimulation and modulation of the host immune 
system, e.g. by reducing production of pro-
inflammatory cytokines through actions on NFκB 
pathways, increasing production of anti-
inflammatory cytokines such as IL-10  
  Modulation of cell proliferation and apoptosis eg. 
Prevention of cytokine induced apotosis 
  Killing or inhibition of growth of pathogens 
through production of bacteriocins or other 
products, such as acid or peroxide, which are 
antagonistic towards pathogenic bacteria. 
  Probiotics can also modify the surrounding 
environment by modulating the pH and/or the 
oxidation–reduction potential, which may 
compromise the ability of pathogens to become 
established. 
 
Prebiotics 
The major mechanism of action of prebiotics is 
assumed to be indirect, i.e. facilitating the proliferation of 
beneficial components of the resident microflora. Some 
prebiotics also exert direct effects on the host; 
independent of their effects on resident bacterial 
populations. [13] These include stimulation of expression 
of IL-10 and interferon γ, enhancement of IgA secretion, 
modulation of inflammatory responses to pathogens and 
stabilization of the gut mucosal barrier. Additionally, 
prebiotics with enhanced function have been designed. 
These oligosaccharide derivatives contain sugars that are 
specific epithelial cell receptors to which pathogens 
adhere and they, therefore, provide „decoy” adhesion 
sites and cause pathogens to adhere to luminal contents 
rather than to epithelial cells. [14]  
 
Oral microbiota in health and disease 
               More than 700 species have been detected in 
the human mouth and the resident microbiota of an 
individual may comprise 30 to >100 species.15 A wide 
variety of sites in the mouth are heavily colonized. 
Supragingival and subgingival plaque form through 
sequential and specific adhesive interactions that result in 
a complex climax community. [16] The tongue is heavily 
colonized and micro-organisms on the dorsum of the 
tongue are reservoirs for supragingival and subgingival 
plaque and salivary microbial populations. [17] Many oral 
bacteria, especially streptococci, also survive within 
buccal epithelial cells. [18] 
 
Functions of the resident microbiota 
Resident microbiota does not play merely a 
passive role, but actively contributes to the maintenance 
of health. The large, diverse resident microbial 
communities that colonize mucosal sites co-exist with a 
host, producing harmful effects only if the host becomes 
immunocompromised, if the resident microbial 
populations are suppressed or if micro-organisms reach 
sites to which they do not normally have access (i.e. 
through trauma). Resident microbial populations 
contribute to host protection through development of the 
immune system, [19] the maintenance of healthy oral 
tissue by influencing expression of mediators such as 
intracellular adhesion molecule 1 (ICAM-1), E-selectin 
and IL-8, [20] modulating immune responses and 
enhancing cellular homeostatic mechanisms. [21] 
 
Defining the resident microbiota 
Resident oral microbial populations are site-
specific as well as highly diverse.  Kilian et al. [22] list the 
following species as „true” oral commensal 
microorganisms: Streptococcus mitis, Streptococcus 
oralis, Actinomyces naeslundii, Fusobacterium nucleatum, 
Haemophilus parainfluenzae, Eikenella corrodens and 
some species of Prevotella. 
 
Microbial populations associated with oral disease 
The most common oral diseases are caries and 
periodontitis, which result from a shift in the balance of the 
resident microbiota at a site. In caries, there are increases Journal of Medicine and Life Vol. 4, Issue 4, October‐December 2011 
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in acidogenic and acid-tolerating species such as mutans 
streptococci and lactobacilli, although other bacteria with 
similar properties can also be found and bifidobacteria, 
non-mutans streptococci, Actinomyces spp., 
Propionibacterium spp., Veillonella spp. and Atopobium 
spp. have also been implicated as significant in the 
etiology of this disease. [23] 
In periodontal diseases, there is an increase in 
plaque mass and a shift towards obligatory anaerobic and 
proteolytic bacteria, many of which are Gram negative 
and currently unculturable. The host damage that occurs 
during periodontal disease arises through the combined 
activities of subgingival biofilms and the host responses to 
these diverse bacterial populations. [16] 
Candida albicans and other Candida species are 
present in low levels in oral microbial communities and 
can cause oral candidiasis and denture- associated 
stomatitis. [24] Halitosis is most often the result of 
production of malodorous metabolic endproducts 
(especially volatile sulphur compounds) by oral bacteria, 
in particular Gram negative anaerobes. [25] 
 
Probiotics of interest 
The most common probiotic strains belong to the 
genera  Lactobacillus and Bifidobacterium.  Lactobacillus 
species from which probiotic strains have been isolated 
include  L. acidophilus, L. johnsonii, L. casei, L. 
rhamnosus, L. gasseri, and L. reuteri. Similarly,  the 
bifidobacterium strains include B. bifidum, B. longum, and 
B. infantis. Lactobacilli can produce different antimicrobial 
components including organic acids, hydrogen peroxide, 
low-molecular weight antimicrobial substances, 
bacteriocins and adhesion inhibitors and thus have gained 
prominence as probiotics. Streptococcus Oralis and 
Streptococcus Uberis have been shown to inhibit the 
growth of pathogens both in the laboratory and animal 
models. [26]  
 
Probiotics in prevention of periodontal diseases 
Periodontal disease is classified into 2 types: 
gingivitis and periodontitis. Gingivitis is characterized by 
inflammation limited to the gingiva, whereas periodontitis 
is a progressive, destructive disease that affects all 
supporting tissues of the teeth, including the alveolar 
bone. [27] The main pathogenic agents associated with 
periodontitis are P. gingivalis, Treponema denticola, 
Tannerella forsythus and Aggregatibacter 
actinomycetemcomitans. [27] These bacteria have a 
variety of virulent characteristics allowing them to colonize 
the subgingival sites, escape the host”s defense system 
and cause tissue damage. [27] The persistence of the 
host”s immune response also constitutes a determining 
factor in progression of the disease. [27] 
There are fewer experimental studies exploring 
probiotic use in periodontal diseases, partly reflecting a 
poorer understanding of the precise etiology of the 
disease and of the conditions that promote health. 
Grudianov et al [28] studied the effect of probiotic tablets on 
gingivitis and different grades of periodontitis and observed that 
probiotic treatment resulted in better microbiota normalization 
than control group. In one recent study, the prevalence of 
lactobacilli, particularly L. gasseri and L. fermentum, in the 
oral cavity was greater among healthy participants than 
among patients with chronic periodontitis. [29] Various 
studies have reported the capacity of lactobacilli to inhibit 
the growth of periodontopathogens, including P. 
gingivalis,  Prevotella intermedia and  A. 
actinomycetemcomitans. [29] Together, these 
observations suggest that lactobacilli residing in the oral 
cavity could play a role in the oral ecological balance. 
In a study by Krasse et al, [30] patients with 
moderate to severe gingivitis who were given either one 
of two L. reuteri formulations had reduced plaque and 
gingivitis scores compared to a placebo group. Although 
the exact mechanisms of action of L. reuteri remain to be 
elucidated, previous studies have suggested at least 3 
plausible possibilities: first, L. reuteri is known for its 
secretion of 2 bacteriocins, reuterin and reutericyclin, that 
inhibit the growth of a wide variety of pathogens; [31] 
second, L. reuteri has a strong capacity to adhere to host 
tissues, thereby competing with pathogenic bacteria; [32] 
and third, the recognized anti-inflammatory effects of L. 
reuteri on the intestinal mucosa, leading to inhibition of 
secretion of proinflammatory cytokines, could be the 
foundation for a direct or indirect beneficial effect of this 
bacterium on people with periodontal disease. Vivekanda 
et al [33] also confirmed the plaque inhibitory, anti-
inflammatory and antimicrobial effects of L. reuteri 
Prodentis. 
Riccia and colleagues [34] recently studied the 
anti-inflammatory effects of Lactobacillus brevis in a group 
of patients with chronic periodontitis. A significant 
reduction in salivary levels of prostaglandin E2 (PGE2) 
and matrix metalloproteinases (MMPs) was observed. 
The authors suggested that the beneficial anti-
inflammatory effects of L. brevis could be attributed to its 
capacity to prevent the production of nitric oxide and, 
consequently, the release of PGE2 and the activation of 
MMPs induced by the nitric oxide. [34] However, L. brevis 
may also be antagonistic, leading to a reduction in the 
quantity of plaque and therefore an improvement in the 
gingival index. 
Shimauchi et al [35]  reported that the regular 
(three times daily for eight weeks) intake of tablets 
containing Lactobacillus salivarius resulted in benefits in 
terms of pocket probing depth and plaque index in 
individuals at high risk of periodontal disease (smokers) 
compared to a placebo control group. [35] Other studies 
have aimed to identify organisms that have the potential 
for probiotic action that may protect against periodontal 
diseases. Some oral strains of lactobacilli and 
streptococci [36] and bifidobacteria [37] have been 
reported to have in vitro inhibitory activity against 
periodontal pathogens, while others are more active Journal of Medicine and Life Vol. 4, Issue 4, October‐December 2011 
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against mutans streptococci. [36] Koll-Klais et al [38] 
observed that Lactobacillus gasseri strains isolated from 
periodontally healthy subjects were more efficient at 
inhibiting the growth of A. actinomycetemcomitans than 
strains from periodontally diseased subjects. L. gasseri 
also inhibited the growth of P. gingivalis and P. 
intermedia; this correlated with an inverse relationship 
between carriage of homofermentative lactobacilli and 
subgingival colonization by A. actinomycetemcomitans, P. 
gingivalis and P. intermedia. Ishikawa et al. [39] observed 
in vitro inhibition of P. gingivalis, P. intermedia and 
Prevotella nigrescens by L. salivarius. Daily ingestion of L. 
salivarius-containing tablets resulted in reduced salivary 
counts of these black pigmented anaerobes. The 
mechanisms of inhibition of periodontal pathogens have 
not been fully clarified. The inhibitory activity displayed by 
homofermentative lactobacilli against periodontal 
pathogens was principally related to their production of 
acid, not to H2O2 or bacteriocin production. [38] Hojo et al 
[37]  suggested that bifidobacteria inhibit some black 
pigmented anaerobes by competing for an essential 
growth factor, vitamin K, although there was no significant 
relationship between higher bifidobacterial counts and 
lower black-pigmented anaerobe counts. Recently, a 
bacteriocin purified from Lactobacillus casei killed P. 
gingivalis but its use was proposed as a novel 
chemotherapeutic agent rather than as strain 
development for probiotic applications. [40] During the 
fermentation process in milk, Lactobacillus helveticus 
produces short peptides that act on osteoblasts  and 
increase their activity in bone formation. [41]  These 
bioactive peptides could thereby contribute to reducing 
the bone resorption associated with periodontitis. 
Recently Shimazaki and colleagues [42]  used 
epidemiological data to assess the relationship between 
periodontal health and the consumption of dairy products 
such as cheese, milk and yoghurt. The authors found that 
individuals, particularly nonsmokers, who regularly 
consumed yoghurt or beverages containing lactic acid 
exhibited lower probing depths and less loss of clinical 
attachment than individuals who consumed few of these 
dairy products. A similar effect was not observed with milk 
or cheese. By controlling the growth of the pathogens 
responsible for periodontitis, the lactic acid bacteria 
present in yoghurt would be in part responsible for the 
beneficial effects observed.  
Sunstar (Etoy, Switzerland) recently began 
marketing the first probiotic specifically formulated to fight 
periodontal disease. Gum Perio Balance contains a 
patented combination of 2 strains of L. reuteri specially 
selected for their synergetic properties in fighting 
cariogenic bacteria and periodontopathogens. Each dose 
of lozenge contains at least 2 × 108 living cells of L. reuteri 
Prodentis. Users are advised to use a lozenge every day, 
either after a meal or in the evening after brushing their 
teeth, to allow the probiotics to spread throughout the oral 
cavity and attach to the various dental surfaces.  
Guided periodontal pocket recolonization (Bacterial 
replacement therapy) in Periodontics 
“Replacement therapy” is also known as 
“probiotic therapy”. The concept of bacterial replacement 
therapy in periodontics was first introduced by Teughels 
et al in 2007. They reported that the subgingival 
application of a bacterial mixture including Streptococcus 
sanguis, S. salivarius, and Streptococcus mitis after 
scaling and root planing significantly suppressed the re-
colonization of Porphyromonas gulae (canine P. 
gingivalis) and P. intermedia in a beagle dog model. [43] 
Nackaerts et al [44] observed that the subgingival 
application of beneficial oral bacteria (i.e. Streptococcus 
sanguinis, Streptococcus salivarius and S. mitis) delays 
recolonization by periodontal pathogens, reduce 
inflammation, and improve bone density and bone levels 
in a beagle dog model. This guided pocket recolonization 
approach may provide a valuable addition or alternative to 
the armamentarium of treatment options for periodontitis. 
 
Probiotics in prevention of halitosis 
Halitosis has many causes (including 
consumption of particular foods, metabolic disorders, 
respiratory tract infections), but in most cases it is 
associated with an imbalance of the commensal 
microflora of the oral cavity. [45]  More specifically, 
halitosis results from the action of anaerobic bacteria that 
degrade salivary and food proteins to generate amino 
acids, which are in turn transformed into volatile sulphur 
compounds, including hydrogen sulphide and methyl 
mercaptan and dimethyl sulphide. [45] 
There have also been clinical and laboratory 
studies of probiotics in their potential for preventing 
halitosis. Peroxide production by strains of Weissella 
cibaria (commonly present in fermented foods) isolated 
from the mouths of healthy children, inhibited production 
of volatile sulphur compounds that contribute to oral 
malodour by F. nucleatum in vitro and in exhalations 
following mouth-rinsing by adult volunteers with a 
suspension of W. cibaria. [46] The success of W. cibaria 
in reducing malodour may have also been because it 
coaggregated efficiently with F. nucleatum [46] and 
therefore competed with other late/secondary colonizers 
for adhesion sites. Thus, W. cibaria may have probiotic 
activities with potential for prevention of periodontal 
disease. Volatile sulphur compounds, such as H2S and 
mercaptoethanol, are produced by a range of periodontal 
anaerobes. [47] The inhibition of these micro-organisms 
by peroxide from W. cibaria may help reduce subgingival 
plaque pathogenicity while its competition for 
coaggregation sites may reduce the reservoir of micro-
organisms available for transmission into plaque.  
One recent study [48] showed that certain 
bacterial species, including Atopobium parvulum, 
Eubacterium sulci and Solobacterium moorei, 
predominate on the dorsal surface of the tongue among 
people with halitosis. Conversely, another species, Journal of Medicine and Life Vol. 4, Issue 4, October‐December 2011 
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Streptococcus salivarius, was detected most frequently 
among people without halitosis and is therefore 
considered a commensal probiotic of the oral cavity. S. 
salivarius is known to produce bacteriocins, which could 
contribute to reducing the number of bacteria that produce 
volatile sulphur compounds. [49] 
S. salivarius K12 produces salivaricin, a 
lantibiotic with inhibitory activity towards most 
Streptococcus pyogenes. [50] This strain has been 
commercially promoted as a probiotic that is reported to 
be protective against throat infections and oral malodour. 
[50] The importance of strain selection for probiotic use is 
illustrated by the fact that some S. salivarius strains differ 
from K12 in some important activities; one strain 
increased production of malodorous products by 
facilitating P. gingivalis metabolism of salivary mucins [51] 
and another up-regulated IL-8 secretion by oral epithelial 
cells [52] in contrast to the down-regulation observed in 
response to K12. 
 
Residence time of probiotics in oral cavity 
Residence time of probiotics in oral cavity after treat-
ment withdrawal was studied by Çaglar et al. [53] A reduced S. 
mutans level was shown after a two-week use of a L. reuteri-
enriched yoghurt; effects were observed during use and for a 
few days after discontinuation. A loss of L. reuteri colonization 
was observed by Wolf et al. [54] two months after having 
discontinued probiotic use. L. rhamnosus GG administration 
and oral cavity colonization was studied by Yli-Knuuttila et al 
[55]; the authors concluded that permanent colonization in oral 
cavity was unlikely (although possible in some cases) and 
suggested the probiotic to be used on a regular basis. Binding 
strength of 17 Lactobacillus strains and 7 bifidobacteria strains 
to saliva and oral mucous membrane was variable in different 
strains, according to a study by Haukioja et al. [56] Such a 
strength variation caused an increased residence time of 
probiotic in oral cavity. Latency time of probiotic S. salivarius 
K12, 4 tablets/day for 3 days, was assessed in several oral 
cavity areas in a 35-day follow-up, by Horz et al. [57] Probiotic 
could be found on oral mucous membrane, tongue and in 
stimulated saliva for more than 3 weeks, with a gradually 
reduced  S. salivarius K12 level being detected beginning 8 
days after treatment withdrawal. 
 
Potential risks of probiotic therapy 
               Different strains of a species may not all 
possess characteristics that enable them to be probiotics 
and rigorous strain selection for the disease concerned is 
complex but essential. [58] Some probiotic strains have 
been in use for many years and have excellent safety 
records. [59] Most probiotic bacteria are weakly 
proteolytic and, for example, Lactobacillus bulgaricus, 
was shown to be incapable of degrading some host tissue 
components. [60] However, there have been some cases 
of bacteraemia and fungaemia associated with probiotic 
use, although these have been in subjects who are 
immunocompromised, [61] or who suffer from chronic 
disease [59] or short gut syndrome. [62] Other 
predisposing factors include prior prolonged 
hospitalization and prior surgical intervention. [61] An 
individual who had been taking L. rhamnosus in a 
probiotic preparation developed Lactobacillus endocarditis 
following dental treatment. [63] In Finland, however, there 
has not been an increase in bacteremia associated with 
probiotic lactobacilli following the increase in the use of 
these products since 1990. [64] The species that most 
commonly exhibit probiotic benefits are lactobacilli and 
other lactic acid bacteria, and the production of acid is 
often thought to be an important component of their 
protection against pathogenic colonization. However, 
Lactobacillus spp. and acid production by acidogenic 
plaque populations play a significant part in the 
development of caries, and a probiotic strain of L. 
salivarius has been shown to be cariogenic in a rat model. 
[65] A number of probiotic lactobacilli and bifidobacteria 
produce acid from fermentation of dietary sugars in vitro. 
[66] There are conflicting data on the salivary lactobacilli 
levels following probiotic usage. Some studies have 
reported no effects, [67] others have found trends for an 
increase, [68] while others have detected statistically 
significant rises in counts of salivary lactobacilli. [69] 
There is a converse risk in that the control or prevention 
of caries may indirectly affect periodontal pathogens. It 
has been known for many years that streptococci, through 
production of hydrogen peroxide, inhibit the growth of 
putative periodontal pathogens, leading to early proposals 
that interactions between groups of micro-organisms 
within plaque can influence the development of disease or 
actively contribute to the maintenance of health, [70] and 
lactobacilli and bifidobacteria also inhibit the growth of a 
range of periodontal pathogens. [70] It is clear that careful 
selection of the strain to be ingested for a particular 
disease is essential and the mode and timing of 
administration can be crucial, as well as the age and 
health of the individual taking the probiotic. There is a 
sufficient knowledge base for major and minor risk factors 
to have been proposed for administration of probiotics to 
prevent intestinal conditions, [59] but this knowledge base 
for oral applications is clearly more distant. One of the 
biggest problems to overcome may be that the probiotic 
activities and micro-organisms that protect against oral 
disease could increase the risk of development of dental 
caries. Therefore, a prebiotic-type approach to enhance 
endogenous beneficial commensals may be more 
attractive. It will also be a challenge to ensure that modes 
of delivery are developed that provide sufficient retention 
and exposure times in the mouth that will allow probiotics 
to colonies plaque or prebiotics to enter into plaque or 
mucosal biofilms and influence microbial metabolism 
within them. 
Conclusion 
Probiotics are emerging as a fascinating field in 
oral medicine. This concept prompts a new horizon on the Journal of Medicine and Life Vol. 4, Issue 4, October‐December 2011 
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relationship between diet and oral health. The use of 
probiotics for use in oral care applications is gaining 
momentum. There is increasing evidence that the use of 
existing probiotic strains can deliver oral health benefits. 
Further work will be needed to fully optimize and quantify 
the extent of this benefit. In parallel, the potential of 
prebiotics to maintain and enhance the benefits provided 
by the resident oral microbiota will be investigated. 
However, whether considering probiotics or prebiotics, it 
will be essential to develop an understanding of the broad 
ecological changes induced in the mouth by their 
ingestion and the long-term consequences of their use on 
oral health and disease. Further studies to understand the 
ability of probiotic bacteria to survive, grow, and have a 
therapeutic effect when used for treatment or when added 
to foods, to fix the doses and schedules of administration 
of probiotics. Hence, systematic studies and randomized 
controlled trials are needed to find out the best probiotic 
strains and means of their administration in different oral 
health conditions. Finally, possibilities to genetically 
modify or engineer potential probiotic strains may offer all 
new visions. Better scientific understanding and extended 
research of these tiny forms of life and their effect on 
humans in the treatment of periodontal diseases might 
further broaden the field of potential applications. 
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